Clinical Trial Update: A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial updating the efficacy, safety, and tolerability of rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04